Clover Biopharmaceuticals (2197) Stock Overview

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.